Category: MedtronicSyndicate content

Diabetes: New warnings for Medtronic's Paradigm insulin pumps

April 14, 2014 by Arezu Sarvestani

Australian regulators again warn users of Medtronic's Paradigm insulin pumps of the danger of accidental insulin overdose.

Diabetes: New warnings for Medtronic's Paradigm insulin pumps

Australian healthcare regulators issued renewed warnings to patients using Medtronic's (NYSE:MDT) Paradigm insulin pumps, cautioning that an accidental button-press may result in a potentially dangerous overdose.

TAVI: Medtronic vows to appeal CoreValve ban in patent loss to Edwards Lifesciences

April 14, 2014 by Arezu Sarvestani

Medtech titan Medtronic plans to seek immediate appeal of a preliminary court injunction banning sales of its CoreValve transcatheter aortic valve implantation system.

TAVI: Medtronic has 7 days to appeal CoreValve ban in patent loss to Edwards Lifesciences

TAVI: Court limits U.S. sales of Medtronic's CoreValve

April 11, 2014 by Arezu Sarvestani

Edwards Lifesciences lands a preliminary injunction limiting Medtronic from selling its CoreValve transcatheter aortic valve implantation system in the U.S.

TAVI: Court bans U.S. sales of Medtronic's CoreValve

FDA expands indication for Medtronic pacemakers, defibs

April 11, 2014 by Brad Perriello

The FDA expands the indication for Medtronic's cardiac rhythm management devices to include bi-ventricular pacing in certain patients.

FDA expands indications for Medtronic pacemakers, defibs

Medtronic (NYSE:MDT) said the FDA expanded the indication for some of its cardiac rhythm management devices to include bi-ventricular pacing in certain heart failure patients.

Hypertension: Docs turn on renal denervation | MassDevice.com On Call

April 10, 2014 by Arezu Sarvestani

U.S. and E.U. cardiologists call for a hard check on global sales of renal denervation technology in the wake of Medtronic's disappointing SYMPLICITY HTN-3 study.

MassDevice.com On Call

MASSDEVICE ON CALL — A group of cardiologists is taking a hard stance against renal denervation, calling for medical device manufacturers to stop selling the technology as a treatment for hypertension.

Medtronic wins CE Mark for Evera MRI SureScan ICD

April 9, 2014 by Brad Perriello

Medtronic says it won CE Mark approval in the European Union for its Evera MRI SureScan implantable cardiac defibrillator, claiming it as the world's 1st ICD approved for full-body magnetic resonance imaging scans.

Medtronic wins CE Mark for Evera MRI SureScan ICD

Medtronic (NYSE:MDT) said it won CE Mark approval in the European Union for the world's 1st market-cleared implantable cardiac defibrillator that's safe for full-body magnetic resonance imaging scans, its Evera MRI SureScan ICD.

The Evera device is slated for an immediate launch in Europe, according to a press release.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp